Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery

Mallinckrodt

Status and phase: Completed; Phase 3

Conditions: Ventricular Dysfunction, Left; Hypertension, Pulmonary

Treatments: Drug: IK-3001

Study type: Interventional

Funder types: Industry

Identifiers

NCT01959828

IK-3001-CVS-301

Details and patient eligibility

About

Sixteen Japanese subjects (6 adults/10 children) with peri- and post-operative pulmonary hypertension associated with cardiac surgery will be evaluated at approx. 6 sites for safety and efficacy of IK-3001.

Full description

This is a multi-center, open-label, clinical study of the safety and efficacy of IK-3001 in 16 subjects with peri- and post-operative pulmonary hypertension associated with cardiac surgery. Two primary sub-sets of this patient population will be evaluated in this study:

1. Adults with severe congestive heart failure having LVAD implant
2. Children requiring surgery for congenital heart disease with corresponding PH or having Glenn surgery or Fontan surgery for single-ventricle physiology. Children with severe pulmonary hypertension due to congenital heart disease who require inhaled nitric oxide (iNO) pre-operatively may also be enrolled.

Enrollment: 18 patients

Sex: All

Ages: Under 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subjects must meet one of the following criteria:

   1. Adults, aged 15 to 80 years, with severe congestive heart failure (CHF) and scheduled for left ventricular assist device (LVAD) placement; or
   2. Children, aged < 15 years, scheduled for surgery for congenital heart disease which may associate pulmonary hypertension (PH)(including children with severe PH due to congenital heart failure and with severe hypoxemia secondary to high pulmonary vascular resistance or either a history or a possibility of developing PH crisis, who are deemed by an investigator or subinvestigator to require IK-3001 pre-operatively); or
   3. Children, aged < 15 years, with congenital heart disease and scheduled for Glenn surgery; or
   4. Children, aged < 15 years, with congenital heart disease and scheduled for Fontan surgery.

2. For women of childbearing potential, a negative result for a pregnancy test documented prior to enrollment.

3. Subjects must give written informed consent. If the subject is a minor the subject's legally acceptable representative (parent or legal guardian) must give written informed consent.

Exclusion criteria

1. Lung hypoplasia or other pre-existing severe lung disease;
2. Planned bi-ventricular support;
3. Participation in another clinical trial of an investigational agent within 28 days from the day of informed consent for this study including subjects who are deemed to carry a residual effect of an investigational product lasting more than 28 days from a previous investigational study;
4. Subjects with PH secondary to organic obstructive lesions in pulmonary arteries;
5. Subjects not under mechanical ventilation;
6. Investigator or subinvestigator decision that the subject is unsuitable for this study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

18 participants in 1 patient group

inhaled nitric oxide

Experimental group

Description:

Adults: IK-3001 at start dose 20 ppm; may be increased to 40 ppm at the investigator's or subinvestigator's discretion (up to \~ 24 hrs). Children: IK 3001 at start 10 dose ppm; may be increased to 20 ppm at the investigator's or subinvestigator's discretion (up to \~24 hrs). Treatment with IK-3001 will continue until it is clinically indicated to begin the weaning process from IK-3001.

Treatment:

Drug: IK-3001